Executive interview – Oryzon

Published on 21 November 2018

Oryzon Genomics is a biotech company focused on epigenetics. Iadademstat (Phase IIa) is being explored for acute leukaemias and small-cell lung cancer; Vafidemstat, its CNS product, is in Phase IIa trials in multiple sclerosis, Alzheimer’s disease and aggression. Newer asset ORY-3001 is being developed for certain orphan indications. In this video, the company’s Chief Executive Officer, Carlos Buesa, and Chief Medical Officer Roger Bullock explain the recent R&D progress and expected newsflow.

Share this with friends and colleagues